{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T02:43:55Z","timestamp":1771296235703,"version":"3.50.1"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T00:00:00Z","timestamp":1539216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008021","name":"Bristol-Myers Squibb Canada","doi-asserted-by":"publisher","award":["AI444-401"],"award-info":[{"award-number":["AI444-401"]}],"id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0205600","type":"journal-article","created":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T17:51:15Z","timestamp":1539280275000},"page":"e0205600","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Serum asunaprevir concentrations showing correlation with the extent of liver fibrosis as a factor inducing liver injuries in patients with genotype-1b hepatitis C virus receiving daclatasvir plus asunaprevir therapy"],"prefix":"10.1371","volume":"13","author":[{"given":"Yoshihito","family":"Uchida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayoko","family":"Naiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-ichi","family":"Kouyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayoko","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masamitsu","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Motoya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mie","family":"Inao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuaki","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukinori","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoaki","family":"Tomiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8792-4526","authenticated-orcid":true,"given":"Satoshi","family":"Mochida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2018,10,11]]},"reference":[{"issue":"6","key":"ref1","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/hep.27113","article-title":"Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection","volume":"59","author":"H Kumada","year":"2014","journal-title":"Hepatology"},{"issue":"11","key":"ref2","doi-asserted-by":"crossref","first-page":"e112647","DOI":"10.1371\/journal.pone.0112647","article-title":"A novel simple assay system to quantify the percent HCV-RNA levels of NS5A Y93H mutant strains and Y93 wild-type strains relative to the total HCV-RNA levels to determine the indication for antiviral therapy with NS5A inhibitors","volume":"9","author":"Y Uchida","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"ref3","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s00535-015-1106-8","article-title":"Significance of variants associated with resistance to NS5A inhibitors in Japanese patients with genotype 1b hepatitis C virus infection as evaluated using cycling-probe real-time PCR combined with direct sequencing","volume":"51","author":"Y Uchida","year":"2016","journal-title":"J Gastroenterol"},{"issue":"12","key":"ref4","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1111\/hepr.12673","article-title":"Development of rare resistance-associated variants that are extremely tolerant against NS5A inhibitors during daclatasvir\/asunaprevir therapy by a two-hit mechanism","volume":"46","author":"Y Uchida","year":"2016","journal-title":"Hepatol Res"},{"issue":"7","key":"ref5","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3851\/IMP2660","article-title":"Randomized study of asunaprevir plus pegylated interferon-\u03b1 and ribavirin for previously untreated genotype 1 chronic hepatitis C","volume":"18","author":"JP Bronowicki","year":"2013","journal-title":"Antivir Ther"},{"issue":"5","key":"ref6","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3851\/IMP2730","article-title":"A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection","volume":"19","author":"F Suzuki","year":"2014","journal-title":"Antivir Ther"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest","volume":"46","author":"A Vallet-Pichard","year":"2007","journal-title":"Hepatology"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/srep01065","article-title":"A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis","volume":"3","author":"A Kuno","year":"2013","journal-title":"Sci Rep"},{"issue":"4","key":"ref9","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/cpdd.52","article-title":"Pharmacolinetics of NS3 protease inhibitor, asunaprevir (ASV, BMS-650032), in phase 1 studies in subjects with or without chronic hepatitis C","volume":"2","author":"T Eley","year":"2013","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"4","key":"ref10","first-page":"292","article-title":"Single- and multiple-ascending dose studies to evaluate the safety, tolerability, and pharmacokinetics of daclatasvir and asunaprevir in healthy male Japanese subjects","volume":"53","author":"T Shiozaki","year":"2015","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/hep.27559","article-title":"Drug-induced immunoallergic hepatitis during combination therapy with daclatasvir and asunaprevir","volume":"61","author":"Y Fujii","year":"2015","journal-title":"Hepatology"},{"issue":"6","key":"ref12","first-page":"2064","article-title":"Reply to \u201cDrug-induced immunoallergic hepatitis during combination therapy with daclatasvir and asunaprevir.\u201d","volume":"63","author":"Y Fujii","year":"2016","journal-title":"Hepatology"},{"issue":"3","key":"ref13","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/jmv.24360","article-title":"Relationships between serum asunaprevir concentration and alanine aminotransferase elevation during daclatasvir plus asunaprevir for chronic HCV genotype 1b infection","volume":"88","author":"N Akuta","year":"2016","journal-title":"J Med Virol"},{"issue":"8","key":"ref14","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/hepr.12621","article-title":"Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients","volume":"46","author":"E Miyaki","year":"2016","journal-title":"Hepatol Res"},{"issue":"1","key":"ref15","doi-asserted-by":"crossref","first-page":"64","DOI":"10.4254\/wjh.v9.i1.64","article-title":"Shear wave elastography in hepatitis C patients before and after antiviral therapy","volume":"9","author":"T Suda","year":"2017","journal-title":"World J Hepatol"},{"issue":"5","key":"ref16","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1002\/hep.27305","article-title":"Elevated serum levels of Wisteria floribunda agglutinin-positive Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients","volume":"60","author":"K Yamasaki","year":"2014","journal-title":"Hepatology"},{"issue":"3","key":"ref17","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/jgh.13511","article-title":"Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients","volume":"32","author":"K Morio","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3851\/IMP2773","article-title":"The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor","volume":"20","author":"T Eley","year":"2015","journal-title":"Antivir Ther"},{"issue":"6","key":"ref19","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1473-3099(15)70099-X","article-title":"Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial","volume":"15","author":"M Mizokami","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"ref20","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1007\/s00535-015-1063-2","article-title":"Clinicopathological characteristics and diagnostic performance of Wisteria floribunda agglutinin positive Mac-2-binding protein as a preoperative serum marker of liver fibrosis in hepatocellular carcinoma","volume":"50","author":"M Fujiyoshi","year":"2015","journal-title":"J Gastroenterol"},{"issue":"12","key":"ref21","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1007\/s00535-017-1345-y","article-title":"Wisteria floribunda agglutinin positive Mac-2-binding protein level increases in patients with acute liver injury","volume":"52","author":"K Morio","year":"2017","journal-title":"J Gastroenterol"},{"issue":"7","key":"ref22","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00535-016-1162-8","article-title":"Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C","volume":"51","author":"G Suda","year":"2016","journal-title":"J Gastroenterol"},{"issue":"7","key":"ref23","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00535-016-1174-4","article-title":"Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis","volume":"51","author":"H Toyoda","year":"2016","journal-title":"J Gastroenterol"},{"issue":"1","key":"ref24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00535-017-1353-y","article-title":"Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan","volume":"53","author":"G Suda","year":"2018","journal-title":"J Gastroenterol"},{"issue":"4","key":"ref25","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jhep.2013.11.013","article-title":"Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting","volume":"60","author":"S Tischer","year":"2014","journal-title":"J Hepatol"},{"issue":"10","key":"ref26","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nrgastro.2013.106","article-title":"Drug-drug interactions during antiviral therapy for chronic hepatitis C","volume":"10","author":"JJ Kiser","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"10","key":"ref27","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1517\/14740338.2015.1084287","article-title":"Asunaprevir for hepatitis C: a safety evaluation","volume":"14","author":"I Gentile","year":"2015","journal-title":"Expert Opin Drug Saf"},{"issue":"9","key":"ref28","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1124\/dmd.107.020073","article-title":"Decreased expression of cytochromes P450 1A2, 2E1, and 3A4 and drug transporters Na+-taurocholate-cotransporting polypeptide, organic cation transporter 1, and organic anion-transporting peptide-C correlates with the progression of liver fibrosis in chronic hepatitis C patients","volume":"36","author":"K Nakai","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"ref29","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1007\/s00535-017-1405-3","article-title":"Association between alanine aminotransferase elevation and UGT1A1*6 polymorphisms in daclatasvir and asunaprevir combination therapy for chronic hepatitis C","volume":"53","author":"S Maekawa","year":"2018","journal-title":"J Gastroenterol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0205600","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T08:51:33Z","timestamp":1589014293000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0205600"}},"subtitle":[],"editor":[{"given":"Tatsuo","family":"Kanda","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,10,11]]},"references-count":29,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,10,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0205600","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,11]]}}}